Investors are funneling billions of dollars into the life sciences industry, helping early-stage biotech companies—responsible for bringing nearly two-thirds of new products to market in the past decade—discover new therapies, make a positive clinical impact and grow. But first, they need to find more space—and finding any lab space in today’s market is nearly impossible, with demand high and supply nearly dried up. 

Meanwhile, midsize biotech companies are facing a bear market and trying to conserve cash to weather the slowdown. One way they’re doing this: by subleasing excess space for the near future. This has given scaling companies a huge opportunity to get the space they need with more flexible leases.

How do these deals work? Robert Coughlin, managing director of JLL's life sciences practice, explains.

James Cook is the director of retail research in the Americas for JLL. Subscribe: Apple Podcasts | Spotify | Google Podcasts Listen on the web: BuildingPlaces.show

Leave a message on the podcast hotline. We may use it on an upcoming show. Call (602) 633-4061

Read more real estate research here.